COCP

Cocrystal Pharma, Inc. COCP

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 28 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$105.0K

Quarter to Jun 30

Net income

$-3.16M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.17M total
VANGUARD CAPITAL MANAGEMENT LLC
$376.1K+49.3%
RENAISSANCE TECHNOLOGIES LLC
$188.6K+44.9%
TWO SIGMA INVESTMENTS, LP
$184.1KNew
GEODE CAPITAL MANAGEMENT, LLC
$80.0K-15.5%
BlackRock, Inc.
$77.4K0.0%
CITADEL ADVISORS LLC
$47.4KNew
Neuberger Berman Group LLC
$33.5K0.0%
XTX Topco Ltd
$30.8K-18.6%
JANE STREET GROUP, LLC
$27.0K+102.7%
VANGUARD FIDUCIARY TRUST CO
$25.2K0.0%
STATE STREET CORP
$21.6K0.0%
HRT FINANCIAL LP
$21.0KNew
Parallel Advisors, LLC
$13.2K0.0%
NORTHERN TRUST CORP
$12.5K0.0%
Ground Swell Capital, LLC
$11.3KNew
WELLS FARGO & COMPANY/MN
$6.6K-11.1%
UBS Group AG
$4.3K-11.0%
Tower Research Capital LLC (TRC)
$4.2K-6.2%
MORGAN STANLEY
$915-8.1%
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
$8580.0%
Clean Yield Group
$4390.0%
NVWM, LLC
$880.0%
BARCLAYS PLC
$44New
SBI Securities Co., Ltd.
$350.0%
Allied Private Wealth LLC
$31--
See all 28 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/COCP

Earnings Per Share

13fpro.ai/company/COCP

Loading ratio trend…

COCP key financials by period

Reported revenue, net income and operating margin by fiscal year, from Cocrystal Pharma, Inc.'s annual filings on SEC EDGAR.

Cocrystal Pharma, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2020$2.0M$-9.6M—
FY 2019$6.6M$-48.2M—
FY 2015$180.0K$-50.1M—
FY 2014$96.0K$-99.0K—
FY 2013$3.3M$-3.9M-122.0%
FY 2011$12.7M$-5.5M-30.6%
Source: COCP filings on SEC EDGAR →

COCP insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Cocrystal Pharma, Inc. (COCP): stock profile, AI score and financials

Cocrystal Pharma, Inc. (COCP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. COCP is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 28 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q2 2026), Cocrystal Pharma, Inc. reports quarterly revenue of $105.0K, net income of $-3.2M. Top institutional holders of COCP by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, TWO SIGMA INVESTMENTS, based on the most recent SEC filings. COCP trades on the Nasdaq exchange and files with the SEC under CIK 1412486. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COCP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cocrystal Pharma, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1412486 →